Condition: Hepatitis B, Chronic · Sponsor: AusperBio Therapeutics Inc.
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with Nucleos(t)ide Analogue (NAs).
This description comes directly from the study's public registry record.
Debbie Liao · (650) 650-2877 · ausperbioclinicaltrials@ausperbio.com
Toll Free-North America · (866) 928-7737
Always discuss trial participation with your own doctor first.
| St Vincents Hospital Melbourne | Fitzroy, Victoria, Australia | Recruiting |
| Queen Mary Hospital - PPDS | Hong Kong, China | Recruiting |
| New Zealand Clinical Research | Grafton, Auckland, New Zealand | Recruiting |
| National University Hospital - Singapore | Singapore, Singapore | Not Yet Recruiting |
| Asan Medical Center | Seoul, South Korea | Not Yet Recruiting |
| Chiayi Christian Hospital | Chiayi City, Taiwan | Not Yet Recruiting |
| E-DA Hospital | Kaohsiung City, Taiwan | Not Yet Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07370207